• The Journal of Internal Korean Medicine
• /
• v.20 no.1
• /
• pp.263-273
• /
• 1999

Cheung-Gan-Haeju tang has been used on 3 cases of alcoholic liver disease patients complicated with ascites, clinical symptom(fatigue. jaundice, urine dark, indigestion, anorexia. ascites etc), liver function (AST, ALT, ${\gamma}$-GT, ALP, total bilirubin), and index of nutritional state (total protein, albumin, cholesterol) were improved after the adminstration. Although the exact mechanism involved in the effects of Cheung-Gan-haeju tang on these disease is still unknown, it is possibly suspected that Cheung-Gan-Haeju tang is non-toxic to liver and has beneficial effects on treating alcoholic liver disease complicated ascites. Further reports with many case, however, will be needed.

• The Journal of Internal Korean Medicine
• /
• v.21 no.4
• /
• pp.649-653
• /
• 2000

We had applied Saenggangunbitang, Gamijihwangtang, and Saenggangunbitang-Gamijihwangtang on a alcoholic liver disease patient with diabetes mellitus, Saenggangunbitang has been used to treat alcoholic liver disease and had known to have beneficial effects. Gamijihwangtang has been used to treat Yin deficiency syndrome in Orient Medicine. We observed clinical symptom, liver function, nutritional state and blood sugar. After first administration, Clinical symptom and blood sugar were improved by Gamijihwangtang medication. Alter second administration, Clinical symptom, blood sugar and liver function were improved by Saenggangunbitang-Gamijihwangtang medication. After third administration, clinical symptom and liver function were improved by Saenggangunbitang medication. It is possibly suggested that Saenggangunbitang-Gamijihwangtang medication has a therapeutic effect on alcoholic liver disease with diabetes mellitus.

• The Journal of Internal Korean Medicine
• /
• v.31 no.2
• /
• pp.356-364
• /
• 2010

Objectives : This study was done to evaluate the effect of stopping drinking, using alcoholic liver disease questionnaire, Diagnosis System of Oriental Medicine (DSOM) and Health Related Quality of Life (HRQOL). Methods : 49 men who satisfied the requirement participated in this trial. They stopped drinking for 6 weeks. They were analyzed using DSOM, alcoholic liver disease questionnaire and SF-36. The data were classified by age (<47,$\geq$48) and alcoholic intake per day (<100g,$\geq$100g). For HRQOL, the SF-36v2 Health Survey was used and Quality Metric Health Outcomes Scoring Software 2.0 (QualityMetric, Lincoln, RI, USA) was applied for the analysis. Results : The alcoholic liver disease questionnaire had a partial correlation with DSOM. Generally stopping drinking decreased Heat (熱). Especially in the group drinking over 100g per day, the correlation was high. In the group over 48 years old, spleen (脾) was improved comparatively. In the group with low HRQOL (PCS<31.43, MCS<23.33) deficiency (虛) was improved. Conclusions : We found that stopping drinking can improve pathogenic factors of alcoholic liver disease and the alcoholic liver disease questionnaire be a useful diagnostic method on alcoholic liver disease by comparison with DSOM.

• The Journal of Korean Medicine
• /
• v.32 no.3
• /
• pp.44-49
• /
• 2011

Objective: This study aimed to get information on the current status of therapies to date for non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH). Methods: All randomized clinical controlled trial (RCT)-derived papers for NAFLD or NASH were reviewed via PubMed Database. Results: 39 RCTs met the review criteria, of which 15 and 24 papers were for NAFLD and NASH, respectively. 83% of the papers were released since 2006, and 30 studies were conducted for western medicines, antioxidants and lifestyle intervention whereas nine trials were done using herbal medicine or acupuncture which showed positive outcome. Conclusions: NAFLD and NASH are new epidemic disorders which can be a target of traditional Oriental medicine. This study will be helpful for the Oriental medicine-based strategies or therapeutic development for them.

• The Journal of Internal Korean Medicine
• /
• v.41 no.5
• /
• pp.740-744
• /
• 2020

Objective: The aim of this study was to report on the effectiveness of Chunggan-tang in a patient with non-alcoholic fatty liver disease. Methods: A 57-year-old woman diagnosed with non-alcoholic fatty liver disease took Chunggan-tang from March 27. 2019 to April 3. 2019. We observed her laboratory findings. Results: After treatment, her laboratory findings showed a reduction in liver enzyme levels. Conclusion: This study shows that Chunggan-tang may be an effective treatment for non-alcoholic fatty liver disease.

• The Korean Journal of Physiology and Pharmacology
• /
• v.27 no.4
• /
• pp.299-310
• /
• 2023

Non-alcoholic fatty liver disease (NAFLD) is a complex disorder characterized by the accumulation of fat in the liver in the absence of excessive alcohol consumption. It is one of the most common liver diseases worldwide, affecting approximately 25% of the global population. It is closely associated with obesity, type 2 diabetes, and metabolic syndrome. Moreover, NAFLD can progress to non-alcoholic steatohepatitis, which can cause liver cirrhosis, liver failure, and hepatocellular carcinoma. Currently, there are no approved drugs for the treatment of NAFLD. Therefore, the development of effective drugs is essential for NAFLD treatment. In this article, we discuss the experimental models and novel therapeutic targets for NAFLD. Additionally, we propose new strategies for the development of drugs for NAFLD.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• v.12 no.sup1
• /
• pp.62-71
• /
• 2009

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of pediatric liver disease. Similar to NAFLD in adults, NAFLD in children is associated with obesity and insulin resistance and requires liver histology for diagnosis and staging. However, significant histological differences exist between adult and pediatric NAFLD. The rise in childhood obesity has been accompanied by an increase in pediatric NAFLD. Age, gender and race/ethnicity are significant determinants of risk, and sex hormones, insulin sensitivity and adipocytokines are implicated in the pathogenesis of pediatric NAFLD. There is no consensus for treatment of NAFLD, however, data suggest that diet, exercise and some pharmacological therapies may be of benefit. To evaluate and effectively treat pediatric NAFLD, the pathophysiology and natural history of the disease should be clarified and non-invasive methods for screening, diagnosis, and longitudinal assessment developed.

• Journal of Ginseng Research
• /
• v.45 no.3
• /
• pp.380-389
• /
• 2021

Metabolic syndrome (MS) refers to a clustering of at least three of the following medical conditions: high blood pressure, abdominal obesity, hyperglycemia, low high-density lipoprotein level, and high serum triglycerides. MS is related to a wide range of diseases which includes obesity, diabetes, insulin resistance, cardiovascular disease, dyslipidemia, or non-alcoholic fatty liver disease. There remains an ongoing need for improved treatment strategies for MS. The most important risk factors are dietary pattern, genetics, old age, lack of exercise, disrupted biology, medication usage, and excessive alcohol consumption, but pathophysiology of MS has not been completely identified. Korean Red Ginseng (KRG) refers to steamed/dried ginseng, traditionally associated with beneficial effects such as anti-inflammation, anti-fatigue, anti-obesity, anti-oxidant, and anti-cancer effects. KRG has been often used in traditional medicine to treat multiple metabolic conditions. This paper summarizes the effects of KRG in MS and related diseases such as obesity, cardiovascular disease, insulin resistance, diabetes, dyslipidemia, or non-alcoholic fatty liver disease based on experimental research and clinical studies.

• Journal of Korean Medicine for Obesity Research
• /
• v.7 no.2
• /
• pp.85-94
• /
• 2007

Objectives The purpose of this study was to investigate the clinical effect of oriental medical obesity therapy on obese patient with non-alcoholic fatty liver disease. We supposed to treat patient 21 years old that had non-alcoholic fatty liver with oriental medical obesity therapy. Methods The patient was treated from the 19th of July to the 22th of August for obesity treatment. And the patient had intensive care through admission treatment from the 19th of July to the 30th of July. Herbal medicine, low calorie and low cholesterol diet, electrolipolysis, auricular acupuncture, aerobic exercise was done during the treatment period. Results His body weight decreased from 107.10㎏ to 98.85㎏. The BMI decreased from 36.2㎏/$m^2$ to 34.5㎏/$m^2$. Abdominal visceral fat tissue decreased from 190.80$cm^2$ to 145.05$cm^2$. AST was decreased from 113 to 45. ALT was decreased from 145 to 40. r-GT was decreased from 123 to 51. Oriental obesity therapy could be effective to treat obese patient with non-alcoholic fatty liver disease. Conclusions The obese patient with non-alcoholic fatty liver disease had improved liver function after oriental obesity treatment.

• Herbal Formula Science
• /
• v.28 no.2
• /
• pp.189-198
• /
• 2020

Objectives : This study investigated the liver-protective effects of MJY2018, a Herbal formula, against alcoholic fatty liver disease and anti-oxidative effects. Methods : Its effects were investigated in an alcoholic fatty liver disease model in male C57BL/6 mice, which were fed Lieber-DeCarli liquid diet containing ethanol. MJY2018 (100 and 200 mg/kg bw/day) or silymarin (50 mg/kg bw/day) were orally administered daily in the alcoholic fatty liver disease mice for 16 days. Results : The results indicate that MJY2018 promotes hepatoprotection by significantly reducing aspartate transaminase (AST) and alanine transaminase (ALT) levels as indicators of liver damage in the serum. Furthermore, MJY2018 reduced accumulation of triglyceride and total cholesterol, increased levels of superoxide dismutase (SOD) and glutathione (GSH) in the livers of the alcoholic fatty liver disease mice model. Additionally, it improved the serum alcohol dehydrogenase (ADH) activity. Conclusions : These results indicate that MJY2018 were effective in improving and protecting oxidative stress and alcoholic liver disease.